Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review

References

• Albers S, Meibohm B, Mir TS, Laer S. 2008. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol. 65:511–522.
   PubMed Web of Science ®Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. 2017. Drug metabolism in the liver. Clin Liver Dis. 21:1–20.
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. 2015. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7:17–29.
   PubMed Web of Science ®Google Scholar
• Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. 2014. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drugs Context. 3:212265.
   PubMedGoogle Scholar
• Bento J, Duarte R, Brito MC, Leite S, Lobato MR, Caldeira MDC, Carvalho A. 2010. Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis. BMJ Case Reports. 2010:bcr1220092554.
   PubMedGoogle Scholar
• Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sorgel F. 2010. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 54:1275–1282.
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Kinzig M, Landersdorfer CB, Holzgrabe U, Stephan U, Sorgel F. 2011. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 55:2927–2936.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 40:327–341.
   PubMed Web of Science ®Google Scholar
• Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. 1972. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 286:912–918.
   PubMed Web of Science ®Google Scholar
• Caldwell J, Gardner I, Swales N. 1995. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol. 23:102–114.
   PubMed Web of Science ®Google Scholar
• Carlton LD, Pollack GM, Brouwer KL. 1996. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol. J Pharm Sci. 85:473–477.
   PubMed Web of Science ®Google Scholar
• Chang SW, Pan WS, Lozano BD, Oleyda BL, Solano MA, Tuero I, Friedland JS, Torrico F, Gilman RH. 2013. Gut Hormones, appetite suppression and cachexia in patients with pulmonary TB. PLoS One. 8:e54564.
   PubMed Web of Science ®Google Scholar
• Cicoira M, Anker SD, Ronco C. 2011. Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle. 2:135–142.
   PubMed Web of Science ®Google Scholar
• Congleton J. 1999. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc. 58:321–328.
   PubMed Web of Science ®Google Scholar
• Coyne KM, Pozniak AL, Lamorde M, Boffito M. 2009. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS. 23:437–446.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (ADAM)” model. CDM. 11:716–729.
   Google Scholar
• De Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, Cleland JG. 2006. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 27:569–581.
   PubMed Web of Science ®Google Scholar
• Deans C, Wigmore SJ. 2005. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269.
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. 2008. Cachexia: a new definition. Clin Nutr. 27:793–799.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. 2011. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12:489–495.
   PubMed Web of Science ®Google Scholar
• Fearon KCH, Preston T. 1990. Body composition in cancer cachexia. Transfus Med Hemother.17:63–66.
   Google Scholar
• Fricker M, Goggins BJ, Mateer S, Jones B, Kim RY, Gellatly SL, Jarnicki AG, Powell N, Oliver BG, Radford-Smith G. 2018. Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight. 3:e94040.
   PubMed Web of Science ®Google Scholar
• George J, Byth K, Farrell GC. 1996. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol. 11:33–39.
   PubMed Web of Science ®Google Scholar
• Gjerde B, Bakke PS, Ueland T, Hardie JA, Eagan TML. 2012. The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respir Med. 106:361–366.
   PubMed Web of Science ®Google Scholar
• Johnston C, Hilmer SN, Mclachlan A, Matthews S, Carroll PR, Kirkpatrick CM. 2014. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 70:549–555.
   PubMed Web of Science ®Google Scholar
• Kazeem A, Oshikoya HM, Sammons IC. 2010. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 66:1025–1035.
   PubMed Web of Science ®Google Scholar
• Kumar RV, Gokhale SV, Ambaye RY, Shetty PA. 1987. Pharmacokinetics of methotrexate in indian children and its relationship to nutritional status. Chemotherapy. 33:234–239.
   PubMed Web of Science ®Google Scholar
• Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, Kim EH, Park SK, Yoon YR. 2009. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 13:1161–1166.
   PubMed Web of Science ®Google Scholar
• Leopold G, Pabst J, Ungethum W, Buhring KU. 1986. Basic pharmacokinetics of bisoprolol: a new highly Beta1-selective adrenoceptor antagonist. J Clin Pharmacol. 26:616–621.
   PubMed Web of Science ®Google Scholar
• Lipman J, Wallis SC, Boots RJ. 2003. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg. 97:1149–1154.
   PubMed Web of Science ®Google Scholar
• Loncar G, Springer J, Anker M, Doehner W, Lainscak M. 2016. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 7:246–260.
   PubMed Web of Science ®Google Scholar
• Mangoni A, Jansen P, Jackson S. 2009. Clinical pharmacology of ageing. In: Jackson S, Jansen P, Mangoni A, editors. Prescribing for eldely patients. Chichester: Wiley-Blackwell; pp. 1–12.
   Google Scholar
• McGavin JK, Keating GM. 2002. Bisoprolol: a review of its use in chronic heart failure. Drugs. 62:2677–2696.
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, Kautzner J. 2013. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 62:1660–1670.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Bray KM. 1994. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet. 26:292–307.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker S, Argiles J, Aversa Z, Bauer J, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, et al. 2010. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) “ "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics&quot.” Clin Nutr. 29:154–159.
   PubMed Web of Science ®Google Scholar
• Nix DE, Wilton JH, Velasquez N, Budny JL, Lassman HB, Mitchell P, Divan K, Schentag JJ. 1992. Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges. J Antimicrob Chemother. 29:51–57.
   PubMed Web of Science ®Google Scholar
• Park SK, Yoon YR, Lee WC, Jun HM, Shon JH, Kim KA, Park JY, Shin JG. 2002. Pharmacokinetics of ofloxacin in Patients with multidrug-resistant Tuberculosis. Tuberc Respir Dis. 52:128–136.
   Google Scholar
• Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 49:3550–3553.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Macphee AA, Berning SE. 1993. Malabsorption of antimycobacterial medications. N Engl J Med. 329:1122–1123.
   PubMed Web of Science ®Google Scholar
• Pichard C, Kyle UG. 1998. Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care. 1:357–361.
   PubMedGoogle Scholar
• Poggesi I, Strolin Benedetti M, Whomsley R, Lamer SL, Molimard M, Watelet JB. 2009. Pharmacokinetics in special populations. Drug Metab Rev. 41:422–454.
   PubMed Web of Science ®Google Scholar
• Porporato P. 2016. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5:e200.
   PubMed Web of Science ®Google Scholar
• Rahman A, Jafry S, Jeejeebhoy K, Nagpal AD, Pisani B, Agarwala R. 2016. Malnutrition and cachexia in heart failure. Jpen J Parenter Enteral Nutr. 40:475–486.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, et al. 2013. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 17:800–806.
   PubMed Web of Science ®Google Scholar
• Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, et al. 2007. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 50:1561–1569.
   PubMed Web of Science ®Google Scholar
• Sanders KJC, Kneppers AEM, Van de Bool C, Langen RCJ, Schols AMWJ. 2016. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 7:5–22.
   PubMed Web of Science ®Google Scholar
• Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. 2005. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 82:53–59.
   PubMed Web of Science ®Google Scholar
• Semple PD, Watson WS, Beastall GH, Bethel MIF, Grant JK, Hume R. 1979. Diet, absorption, and hormone studies in relation to body weight in obstructive airways disease. Thorax. 34:783–788.
   PubMed Web of Science ®Google Scholar
• Shammas FV, Dickstein K. 1988. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet. 15:94–113.
   PubMed Web of Science ®Google Scholar
• Sharkey RA, Mulloy EMT, O’Neill SJ. 1999. The acute effects of oxygen and carbon dioxide on renal vascular resistance in patients with an acute exacerbation of COPD. Chest. 115:1588–1592.
   PubMed Web of Science ®Google Scholar
• Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. 2001. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 56:746–750.
   PubMed Web of Science ®Google Scholar
• Sica DA. 2003. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congest Heart Fail. 9:287–292.
   PubMedGoogle Scholar
• Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, Bausewein C. 2012. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 15:1374–1381.
   PubMed Web of Science ®Google Scholar
• Strenkoski LC, Nix DE. 1993. Cefpirome clinical pharmacokinetics. Clin Pharmacokinet. 25:263–273.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Tollier C, Richard C. 1990. The effect of respiratory disorders on clinical pharmacokinetic variables. Clin Pharmacokinet. 19:462–490.
   PubMed Web of Science ®Google Scholar
• Tanaka E. 1998. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther. 23:403–416.
   PubMed Web of Science ®Google Scholar
• Te Brake LHM, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, et al. 2015. Exposure to total and protein-unbound rifampin is not affected by malnutrition in indonesian tuberculosis patients. Antimicrob Agents Chemother. 59:3233–3239.
   PubMed Web of Science ®Google Scholar
• Trobec K, Kerec Kos M, Von Haehling S, Springer J, Anker SD, Lainscak M. 2013. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 8:e79603
   PubMed Web of Science ®Google Scholar
• Trobec KC, Grabnar I, Kerec MK, Vovk T, Trontelj J, Anker SD, Rosano G, Lainscak M. 2016. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol. 72:813–822.
   PubMed Web of Science ®Google Scholar
• Urso R, Blardi P, Giorgi G. 2002. A short introduction to pharmacokinetics. Eur Rev Med Pharmacol Sci. 6:33–44.
   PubMedGoogle Scholar
• Von Haehling S, Anker SD. 2014. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 5:261–263.
   PubMed Web of Science ®Google Scholar
• Wagner PD. 2008. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 31:492–501.
   PubMed Web of Science ®Google Scholar
• Welage LS, Schultz RW, Schentag JJ. 1984. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 25:201–204.
   PubMed Web of Science ®Google Scholar
• Woosley RL. 1987. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J. 114:1280–1291.
   PubMed Web of Science ®Google Scholar
• Younge JO, Damen NL, Van Domburg RT, Pedersen SS. 2013. Obesity, health status, and 7-year mortality in percutaneous coronary intervention: in search of an explanation for the obesity paradox. Int J Cardiol. 167:1154–1158.
   PubMed Web of Science ®Google Scholar